EBC-1 Xenograft Model Service for NSCLC

EBC-1 Xenograft Model Service for NSCLC provides a robust, MET-amplified preclinical platform for evaluating targeted therapeutics in non-small cell lung cancer. At Alfa Cytology, we specialize in constructing and validating EBC-1 xenograft models with rigorous quality control, enabling reliable pharmacodynamic and efficacy readouts for your NSCLC drug discovery programs.

Overview of EBC-1 Xenograft Model for NSCLC

The EBC-1 xenograft model is derived from a human lung squamous cell carcinoma and serves as a highly relevant in vivo platform for studying non-small cell lung cancer (NSCLC) driven by MET amplification. Originating from a patient with metastatic disease, the EBC-1 cell line displays epithelial morphology and harbors high-level amplification of the MET proto-oncogene, resulting in constitutive activation of MET-dependent signaling pathways. When implanted subcutaneously into immunodeficient mice, EBC-1 cells produce fast-growing, consistent tumors, making the model particularly suited for evaluating MET-targeted therapeutics, resistance mechanisms, and rational drug combinations. Due to its defined oncogenic dependency, the EBC-1 xenograft model is widely used in translational research aimed at overcoming resistance to tyrosine kinase inhibitors and identifying novel vulnerabilities in MET-amplified NSCLC.

Fig 1. 1E7-Fc targets and accumulates in MET-expressing xenografts.  (Luo, Natalie Y., et al., 2024)

The defining feature of the EBC-1 cell line is its strong MET gene amplification, which drives persistent activation of downstream PI3K/AKT and MAPK signaling cascades. The cell line lacks activating mutations in KRAS and ALK, making it an ideal system for selectively studying MET-targeted therapeutic agents. EBC-1 cells exhibit strong epithelial features, including cytokeratin 5/6 and E-cadherin expression, and moderate levels of PD-L1, providing insight into both oncogenic signaling and immune evasion. The MET dependency in EBC-1 also allows for detailed exploration of resistance mechanisms that arise through bypass pathway activation or secondary mutations.

Cell Line Information: EBC-1

The EBC-1 cell line is a well-characterized human lung squamous cell carcinoma line established from a metastatic skin lesion of a 69-year-old male patient. It is extensively utilized in NSCLC research due to its high-level MET amplification and defined molecular profile. The table below summarizes key biological and molecular characteristics of the EBC-1 cell line.

Our Services

Alfa Cytology leverages the EBC-1 xenograft model to deliver high-quality, reproducible preclinical data for NSCLC therapeutic development. Our integrated service spans model construction, in-life monitoring, pharmacokinetic sampling, and comprehensive endpoint analysis, ensuring seamless support from study design to final report. With extensive experience in MET-amplified tumor models, we provide customized dosing regimens, combination therapy evaluation, and biomarker analysis to accelerate your drug discovery pipeline.

Workflow of EBC-1 Xenograft Model Construction

The construction of EBC-1 xenograft models at Alfa Cytology follows a standardized, quality-controlled workflow designed to ensure tumor take rates, growth consistency, and data reproducibility. Each step is optimized for the aggressive growth profile and MET-driven biology of the EBC-1 cell line.

1. Cell Line Authentication & Quality Control: EBC-1 cells are authenticated via STR profiling and confirmed for MET amplification status by qPCR or FISH. Mycoplasma testing and sterility checks are performed prior to expansion.

2. Cell Expansion & Preparation: Cells are expanded in vitro under standardized conditions (EMEM + 10% FBS, 37°C, 5% CO₂). At 70–80% confluence, cells are harvested using Accutase, washed, and resuspended in serum-free medium at a concentration of 1×10⁷ cells/mL.

3. Matrigel Preparation: Cell suspension is mixed 1:1 with high-concentration Matrigel on ice to enhance tumor take and growth kinetics, particularly for subcutaneous implantation.

4. Animal Preparation & Implantation: Immunodeficient mice (BALB/c nude or NOD-SCID, 6–8 weeks old) are acclimatized for 5–7 days. EBC-1 cells (typically 5×10⁶ cells per mouse in 100–200 µL) are implanted subcutaneously into the right flank using aseptic technique.

5. Tumor Monitoring & Randomization: Tumors are measured twice weekly using digital calipers. Upon reaching 100–200 mm³, mice are randomized into treatment groups based on tumor volume and body weight to minimize bias.

6. Treatment Administration & In-Life Monitoring: Test compounds are administered via the designated route (oral gavage, intraperitoneal, or intravenous) according to the study protocol. Body weight, tumor volume, and clinical signs are recorded throughout the study.

7. Pharmacodynamic & Biomarker Sampling: At predefined time points, tumor and blood samples are collected for pharmacokinetic analysis, MET phosphorylation assessment, and downstream signaling evaluation (p-AKT, p-ERK).

8. Endpoint Analysis & Necropsy: At study termination, tumors are excised, weighed, and processed for histopathology (H&E, IHC for Ki-67, c-MET, p-MET), TUNEL assay, and gene expression analysis. Comprehensive data compilation and statistical analysis are delivered in a final study report.

Fig 2. EBC-1 xenograft model construction workflow.

Case Study-EBC-1 Xenograft Model Development

In a recent preclinical engagement, the EBC-1 xenograft model was utilized to evaluate the efficacy of a novel MET inhibitor in comparison with standard-of-care reference compounds. Following successful model establishment with consistent tumor growth kinetics, dose-dependent tumor growth inhibition was observed across multiple treatment arms, with pharmacodynamic analysis confirming robust suppression of MET phosphorylation and downstream PI3K/AKT signaling. Combination studies integrating the MET inhibitor with radiotherapy demonstrated enhanced anti-tumor activity compared to monotherapy, supporting further investigation into rational combination strategies for MET-amplified NSCLC. These findings illustrate the utility of the EBC-1 model in generating actionable preclinical data for therapeutic development.

Why Choose Alfa Cytology?

Alfa Cytology delivers reliable, scientifically rigorous EBC-1 xenograft model services tailored to accelerate your NSCLC drug discovery programs. Our commitment to quality and client collaboration ensures robust data generation and seamless study execution.

• Extensive experience with MET-amplified tumor models including EBC-1, with validated protocols ensuring high tumor take rates and consistent growth kinetics.
• Comprehensive in-house capabilities spanning model construction, in-life monitoring, pharmacokinetic sampling, and multi-endpoint biomarker analysis.
• Customizable study designs supporting single-agent, combination, and radiotherapy combination assessments with flexible dosing schedules and route options.
• Rigorous quality control including STR authentication, mycoplasma testing, and MET amplification verification to guarantee model fidelity and data reproducibility.
• Dedicated project management with transparent communication, ensuring timely delivery of interim data and comprehensive final reports aligned with regulatory expectations.

Contact Us

Ready to advance your NSCLC therapeutic program with the EBC-1 xenograft model? Contact us today to discuss your study requirements and receive a customized proposal. Our team of experienced scientists is prepared to support your preclinical research from protocol design to data delivery—reach out to us and let Alfa Cytology accelerate your path to the clinic.

For research use only. Not intended for any clinical use.